Bayer AG | Income Statement

Fiscal year is January-December. All values EUR Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
40,157
41,339
46,085
34,943
35,015
39,586
Cost of Goods Sold (COGS) incl. D&A
19,516
19,909
21,040
11,756
11,382
17,010
Gross Income
20,641
21,430
25,045
23,187
23,633
22,576
SG&A Expense
15,129
15,973
18,789
17,502
17,762
18,934
EBIT
-
-
-
-
5,888
3,654
Unusual Expense
753
318
192
75
724
4,022
Non Operating Income/Expense
519
482
415
296
182
3,912
Interest Expense
584
611
751
690
1,061
1,550
Pretax Income
4,223
4,427
5,245
4,779
4,557
2,250
Income Tax
1,021
1,071
1,223
1,017
1,329
607
Equity in Affiliates
16
13
9
6
20
68
Consolidated Net Income
3,186
3,343
4,013
3,756
3,248
1,711
Net Income
3,189
3,326
4,025
3,743
3,249
1,695
Net Income After Extraordinaries
3,189
3,226
3,940
2,955
838
1,695
Net Income Available to Common
3,189
3,426
4,110
4,531
7,336
1,695
EPS (Basic)
3.80
4.14
4.97
5.44
8.41
1.80
Basic Shares Outstanding
840
840
840
846
886
941
EPS (Diluted)
3.80
4.08
4.89
5.36
8.28
1.80
Diluted Shares Outstanding
840
840
840
846
886
941
EBITDA
7,351
8,196
9,383
8,054
8,029
6,653
Other Operating Expense
772
44
25
18
17
12
Non-Operating Interest Income
301
337
322
137
272
256
Minority Interest Expense
3
17
12
13
1
16

About Bayer

View Profile
Address
Kaiser-Wilhelm-Allee 1
Leverkusen Nordrhein-Westfalen 51368
Germany
Employees -
Website http://www.bayer.com
Updated 07/08/2019
Bayer AG engages in the development, manufacture and distribution of products in the areas of health care, nutrition and high-tech materials. It operates through the following segments: Pharmaceuticals, Consumer Health, Crop Science, Animal Health and Covestro. The Pharmaceuticals segment engages in the development, production and marketing of prescription products for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology and ophthalmology; diagnostic imaging equipment and the necessary contrast agents.